Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling

Journal of Molecular Graphics and Modelling

Volumn 23, Issue 2, 2004, Pages 153-165

  Torrent, Maricel ^a   Rickert, Keith ^a   Pan, Bo Sheng ^a   Sepp Lorenzino, Laura ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Activation loop; Homology modeling; Mutations; Oncology; Protein tyrosine kinases

Indexed keywords

ACTIVATION LOOPS; ACTIVE STATES;

ACTIVATION ANALYSIS; CONFORMATIONS; MATHEMATICAL MODELS; MUTAGENESIS; STABILITY;

ENZYMES;

FLT3 LIGAND; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

AMINO ACID SEQUENCE; ARTICLE; COMPARATIVE STUDY; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; GENE DELETION; LEUKEMIA; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY; SIMULATION;

CATALYTIC DOMAIN; COMPUTER SIMULATION; ENZYME ACTIVATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MODELS, MOLECULAR; MUTATION; POINT MUTATION; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; SEQUENCE DELETION; THERMODYNAMICS;

INSERTION SEQUENCES;

EID: 4444311694     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2004.05.002     Document Type: Article

References (70)

1. Lyman S.D., Jacobsen S.E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood. 91:1998;1101-1134
2. Matthews W., Jordan C.T., Gavin M., Jenkins N.A., Copeland N.G., Lemischka I.R. DNase protection analysis of the stable synaptic complexes involved in mu transposition. Proc. Natl. Acad. Sci. USA. 88:1991;9026-9030
3. Stirewalt D.L., Radich J.P. The role of Flt3 in haematopoietic malignancies. Nature Rev. 3:2003;650-665
4. Rombouts W.J., Blokland I., Lowenberg B., Ploemacher R.E. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 14:2000;675-683
5. Meshinchi S., Woods W.G., Stirewalt D.L., Sweetser D.A., Buckley J.D., Tjoa T.K., Bernstein I.D., Radich J.P. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 97:2001;89-94
6. Nakao M., Yokota S., Iwai T. Internal tandem duplication of the Flt3 gene found in acute myeloid leukemia. Leukemia. 10:1996;1911-1918
7. Kiyoi H., Naoe T., Yokota S., Nakao M., Minami S., Kuriyama K., Takeshita A., Saito K., Hasegawa S., Shimodaira S., Tamura J., Shimazaki C., Matsue K., Kobayashi H., Arima N., Suzuki R., Morishita H., Saito H., Ueda R., Ohno R. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia. 11:1997;1447-1452
8. Horiike S., Yokota S., Nakao M., Iwai T., Sasai Y., Kaneko H., Taniwaki M., Kashima K., Fujii H., Abe T., Misawa S. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 11:1997;1442-1446
9. Yokota S., Kiyoi H., Nakao M., Iwai T., Misawa S., Okuda T., Sonoda Y., Abe T., Kahsima K., Matsuo Y., Naoe T. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 11:1997;1605-1609
10. Iwai T., Yokota S., Nakao M., Okamoto T., Taniwaki M., Onodera N., Watanabe A., Kikuta A., Tanaka A., Asami K., Sekine I., Mugishima H., Nishimura Y., Koizumi S., Horikoshi Y., Mimaya J., Ohta S., Nishikawa K., Iwai A., Shimokawa T., Nakayama M., Kawakami K., Gushiken T., Hyakuna N., Katano N., Tsurusawa M., Fujimoto T. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. Leukemia. 13:1999;38-43
11. Xu F., Taki T., Yang H.W., Hanada R., Hongo T., Ohnishi H., Kobayashi M., Bessho F., Yanagisawa M., Hayashi Y. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol. 105:1999;155-162
12. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., Asou N., Kuriyama K., Yagasaki F., Shimazaki C., Akiyama H., Saito K., Nishimura M., Motoji T., Shinagawa K., Takeshita A., Saito H., Ueda R., Ohno R., Naoe T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 97:2001;2434-2439
13. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R., Reilly J.T. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. 113:2001;983-988
14. Beghini A., Peterlongo P., Ripamonti C.B., Larizza L. C-Kit mutations in core binding factors leukemias. Blood. 95:2000;726-727
15. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., Sugahara H., Butterfield J.H., Ashman L.K., Kanayama Y., Matsuzawa Y., Kitamura Y., Kanakura Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1993;1736-1744
16. Spiekermann K., Bagrintseva K., Schoch C., Haferlach T., Hiddemann W., Schnittger S. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood. 100:2002;3423-3425
17. Thiede C., Steudel C., Mohr B., Schaich M., Schäkel U., Platzbecker U., Wermke M., Bornhäuser M., Ritter M., Neubauer A., Ehninger G., Illmer T. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 99:2002;4326-4335
18. Heinrich M.C., Griffith D.J., Druker B.J., Walt C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932
19. Weisberg E., Boulton C., Kelly L.M., Manley P., Fabbro D., Meyer T., Gilliland D.G., Griffin J.D. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:2002;433-443
20. Levis M., Allebach J., Tse K.-F., Zheng R., Baldwin B.R., Smith B.D., Jones-Bolin S., Ruggen B., Dionne C., Small D. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 99:2002;3885-3891
21. Kelly L.M., Yu J.-C., Boulton C.L., Apatira M., Li J., Sullivan C.M., Williams I., Amaral S.M., Curley D.P., Duclos N., Neuberg D., Scarborough R.M., Pandey A., Hollenbach S., Abe K., Lokker N.A., Gilliland D.G., Giese N.A. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 1:2002;421-432
22. Tan B.L., Hong L., Munugalavadla V., Kapur R. Functional and biochemical consequences of abrogating the activation of multiple diverse early signaling pathways in Kit. J. Biol. Chem. 278:2003;11686-11695
23. Weiss A., Sclessinger J. Switching signals on or off by receptor dimerization. Cell. 94:1998;277-280
24. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell. 109:2002;275-282
25. Hubbard S.R., Mohammadi M., Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 273:1998;11987-11990
26. Ablooglu A.J., Frankel M., Rusinova E., Ross J.B.A., Kohanski R.A. Multiple activation loop conformations and their regulatory properties in the insulin receptor's kinase domain. J. Biol. Chem. 276:2001;46933-46940
27. Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y.T., Sang B.-C., Nowakowski J., Kassel D.B., Cronin C.N., McRee D.E. Structure of c-Kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278:2003;31461-31464
28. Xu D., Xu Y., Uberbacher E.C. Computational tools for protein modeling. Curr. Protein Pept. Sci. 1:2000;1-21
29. Baker D., Sali A. Protein structure prediction and structural genomics. Science. 294:2001;93-96
30. Liu T., Rojas A., Ye Y.Z., Godzik A. Homology modeling provides insights into the binding model of the PAAD/DAPIN/pyrin domain, a fourth member of the CARD/DD/DED domain family. Protein Sci. 12:2003;1872-1881
31. Fatemi N., Sarkar B. Structural and functional insights of Wilson disease copper-transporting ATPase. J. Bioenerg. Biomembr. 34:2002;339-349
32. Sharma V., Dufel M.W. Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling. J. Med. Chem. 45:2002;5514-5522
33. Chang Y.-T., Loew G. Homology modeling, molecular dynamics simulations, and analysis of CYP119, a P450 enzyme from extreme acidothermophilic archaeon sulfolobus solfataricus. Biochemistry. 39:2000;2484-2498
34. Marhefka C.A., Moore B.M., Bishop T.C., Kirkovsky L., Mukherjee A., Dalton J.Y., Miller D.D. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J. Med. Chem. 44:2001;1729-1740
35. Kiyama R., Tamura Y., Watanabe F., Tsuzuki H., Ohtani M., Yodo M. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J. Med. Chem. 42:1999;1723-1738
36. Kitchen D., Hoffman R.C., Moy F.J., Powers R. Homology model for oncostatin M based on NMR structural data. Biochemistry. 37:1998;10581-10588
37. de Groot M.J., Vermeulen N.P.E., Mullenders D.L.J., Op den Kelder G.M.D. A homology model for rat Mu class glutathione S-transferase 4-4. Chem. Res. Toxicol. 9:1996;28-40
38. Böhmer F.D., Karagyozov L., Ueckert A., Serve H., Botzki A., Mahboobi S., Dove S. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. 278:2003;5148-5155
39. Wilson C.A., Kreychman J., Gerstein M. Assessing annotation transfer for genomics: quantifying the relations between protein sequence. J. Mol. Biol. 297:2000;233-249
40. Mctigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.C., Villafranca J.E., Appelt K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure. 7:1999;319-330
41. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., Schlessinger J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960
42. Mohammadi M., Froum S., Hamby J.M., Schroeder M.C., Panek R.L., Lu G.H., Eliseenkova A.V., Green D., Schlessinger J., Hubbard S.R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17:1998;5896-5904
43. Mohammadi M., Schlessinger J., Hubbard S.R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell. 86:1996;577-587
44. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase..Science. 289:2000;1938-1942
45. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imanitib (STI-571). Cancer Res. 62:2002;4236-4243
46. Hubbard S.R., Wei L., Ellis L., Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 372:1994;746-754
47. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16:1997;5572-5581
48. Boeckmann B., Bairoch A., Apweiler R., Blatter M.-C., Estreicher A., Gasteiger E., Martin M.J., Michoud K., O'Donovan C., Phan I., Pilbout S., Schneider M. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res. 31:2003;365-370
49. Pruitt K.D., Tatusova T., Maglott D.R. NCBI reference sequence project: update and current status. Nucleic Acid Res. 31:2003;34-37
50. NCBI's BLAST services: http://www.ncbi.nlm.nih.gov.
51. http://www.chemcomp.com/fdept/prodinfo.htm.
52. McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.-C., Villafranca J.E., Appelt K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure. 7:1999;319-330
53. Vriend G., Sander C. Quality control of protein models: directional atomic contact analysis. J. Appl. Crystallogr. 26:1993;47-60
54. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:1993;283-291
55. Morley G.M., Uden M., Gullick W.J., Dibb N.J. Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation. Oncogene. 18:1999;3076-3084
56. Moriyama Y., Tsujimura T., Hashimoto K., Morimoto M., Kitayama H., Matsuzawa Y., Kitamura Y., Kanakura Y. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. J. Biol. Chem. 271:1996;3347-3350
57. Fenski R., Flesch K., Serve S., Mizuki M., Oelmann E., Kratz-Albers K., Kienast J., Leo R., Schwartz S., Berdel W.E., Serve H. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br. J. Haematol. 108:2000;322-330
58. Abbadi A., Mcharfi M., Aubry A., Premilat S., Boussard G., Marraud M. Involvement of side functions in peptide structures: the Asx turn. Occurrence and conformational aspects. J. Am. Chem. Soc. 113:1991;2729-2735
59. Aimes R.T., Hemmer W., Taylor S.S. Serine-53 at the tip of the glycine-rich loop of cAMP-dependent protein kinase: role in catalysis, P-site specificity, and interaction with inhibitors. Biochemistry. 39:2000;8325-8332
60. Bossemeyer D. The glycine-rich sequence of protein kinases: a multifunctional element. TIBS. 19:1994;201-205
61. Zheng J., Knighton D.R., Ten Eyck L.F., Karlsson R., Xuong N.H., Taylor S.S., Sowadski J.M. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry. 32:1993;2154-2161
62. Narayana N., Cox S., Shaltiel S., Taylor S.S., Xuong N.-H. Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine. Biochemistry. 36:1997;4438-4448
63. Johnson L.N., Noble M.E., Owen D.J. Active and inactive protein kinases: structural basis for regulation. Cell. 85:1996;149-158
64. Johnson D.A., Leathers V.L., Martinez A.-M., Walsh D.A., Fletcher W.H. Fluorescence resonance energy transfer within a heterochromatic cAMP-dependent protein kinase holoenzyme under equilibrium conditions: new insights into the conformational changes that result in cAMP-dependent activation. Biochemistry. 32:1993;6402-6410
65. Biondi R.M., Komander D., Thomas C.C., Lizcano J.M., Deak M., Alessi D.R., van Aalten D.M.F. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J. 21:2002;4219-4228
66. Warmuth M., Simon N., Mitina O., Mathes R., Fabbro D., Manley P.W., Buchdunger E., Forster K., Moarefi I., Hallek M. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood. 101:2003;664-672
67. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 82:1999;231-239
68. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood. 100:2002;1532-1542
69. Favelyukis S., Till J.H., Hubbard S.R., Miller W.T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Biol. 8:2001;1058-1063
70. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880